Medicine and Health

Subterms

    More stories

    • 163 Shares169 Views

      in Elections

      ‘No Smoking’ Sign on Planes Won’t Need Off Switch After FAA Rule Change

      by

      The Federal Aviation Administration did away with a rule that had required an off switch for the sign even though smoking on U.S. flights ended years ago.The days of airplane cabins hazy with cigarette smoke are long gone, but a reminder of that era is still visible inside commercial jets.Smoking has been banned on commercial flights in the United States for decades, but the Federal Aviation Administration is only just updating an outdated rule to reflect that reality. Starting on Tuesday, the illuminated overhead “No Smoking” sign no longer requires an off switch.That obsolete requirement had become “time-consuming and burdensome” for airlines and airplane manufacturers to comply with, the F.A.A. said in a rule enacting the change. In February, for example, United Airlines was briefly unable to use a handful of new Airbus planes because the “No Smoking” signs on board couldn’t be shut off, causing the airline to delay a few flights. The issue was resolved after the F.A.A. granted United an exemption.Dozens of such exemptions have allowed that requirement to live on while the agency focused on more pressing matters. But the long life of the mandate also reflects how entangled smoking once was with commercial flights, which began in the 1910s.“The rise of aviation literally parallels the rise of the cigarette,” said Alan Blum, the director of the University of Alabama’s Center for the Study of Tobacco and Society.Pipes, cigars and chewing tobacco were once more popular than cigarettes, but that began to change in the early 20th century, according to Dr. Blum. During World War I, cigarettes were added to rations for American soldiers fighting abroad.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 63 Shares129 Views

      in Elections

      What Is Considered ‘Moderate Drinking’?

      by

      That depends on whom you ask, and what country you live in. Here’s what the research suggests and how to think about it.Over the past several years, there has been a rise in alcohol-related deaths and a steady wave of news about the health risks of drinking. Calls for people to drink only in moderation have become more urgent. But what, exactly, does that mean?“Tongue in cheek, people have defined it as not drinking more than your doctor,” said Tim Stockwell, a scientist at the Canadian Institute for Substance Use Research.More officially, in the United States, moderate drinking is defined as one drink or less per day for women and two drinks or less per day for men. But other countries define moderate drinking, also called low-risk drinking, differently, and recent research around alcohol’s health harms has raised questions about current guidelines.How are the guidelines set?Experts used to think that low or moderate amounts of alcohol were good for you. That assumption was based on research showing that people who drank in moderation lived longer than those who abstained or drank excessively. The longevity benefit disappeared around two drinks a day for women and three drinks a day for men, Dr. Stockwell said.But many researchers now think that those conclusions were based on data analyses that had “all kinds of methodological problems,” said Elizabeth Mayer-Davis, a professor of nutrition and medicine at the University of North Carolina, Chapel Hill.For example, one issue was that many people who abstained from alcohol did so because they had existing health problems, while people who drank moderately were more likely to have healthy lifestyle habits. It created “really what was an illusion of health benefits with low to moderate amounts of drinking,” Dr. Mayer-Davis said.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 138 Shares199 Views

      in Elections

      Trump prometió hacer público su historial médico pero sigue sin hacerlo

      by

      Si vuelve a ser elegido, se convertirá en el presidente de mayor edad al final de su mandato. Sin embargo, se niega a revelar incluso la información médica básica.[Estamos en WhatsApp. Empieza a seguirnos ahora]Como candidato presidencial en 2015, Donald Trump se negó a publicar su historial médico, ofreciendo en su lugar una carta de cuatro párrafos de su médico personal en la que proclamaba que sería “la persona más sana jamás elegida para la presidencia”.En 2020, cuando estuvo hospitalizado por COVID-19 y se presentaba a la reelección, los médicos de Trump dieron una información mínima sobre su estado, que, según se supo más tarde, fue mucho más grave de lo que dejó entrever las descripciones públicas.En 2024, días antes de convertirse en el candidato presidencial republicano oficial por tercera vez, fue rozado por una bala de un posible asesino, pero su campaña no celebró una sesión informativa sobre su estado, no publicó los registros hospitalarios ni puso a disposición a los médicos de urgencias que lo trataron para ser entrevistados.Ahora, a poco más de un mes de unas elecciones que podrían convertir a Trump, de 78 años, en la persona de mayor edad en ocupar la presidencia (82 años, 7 meses y 6 días cuando su mandato termine en enero de 2029), se niega a revelar incluso la información más básica sobre su salud.Si gana, Trump podría entrar en el Despacho Oval con una serie de problemas potencialmente preocupantes, según los expertos médicos: factores de riesgo cardíaco, posibles secuelas del intento de asesinato de julio y el deterioro cognitivo que se produce de forma natural con la edad, entre otros.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 163 Shares159 Views

      in Elections

      Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

      by

      Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North Africa to make and sell at a lower price its groundbreaking drug lenacapavir, a twice-yearly injection that provides near-total protection from infection with H.I.V.Those companies will be permitted to sell the drug in 120 countries, including all the countries with the highest rates of H.I.V., which are in sub-Saharan Africa. Gilead will not charge the generic drugmakers for the licenses.Gilead says the deal, made just weeks after clinical trial results showed how well the drug works, will provide rapid and broad access to a medication that has the potential to end the decades-long H.I.V. pandemic.But the deal leaves out most middle- and high-income countries — including Brazil, Colombia, Mexico, China and Russia — that together account for about 20 percent of new H.I.V. infections. Gilead will sell its version of the drug in those countries at higher prices. The omission reflects a widening gulf in health care access that is increasingly isolating the people in the middle.Gilead charges $42,250 per patient per year for lenacapavir in the United States, where it is approved as a treatment for H.I.V. The company has said nothing about what lenacapavir will cost when used to prevent H.I.V. infections, a process called pre-exposure prophylaxis, or PrEP.The generics makers — four companies in India, one in Pakistan and one in Egypt — are expected to sell it for much less. Researchers at Liverpool University found the drug could profitably be produced for as little as $40 per patient per year, if it were being purchased in large volumes.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 125 Shares109 Views

      in Elections

      A Week of Chaos Pushes Lebanon’s Doctors to the Limit

      by

      Dr. Dania El-Hallak was already exhausted. After wireless devices exploded across Lebanon, there had been little time to process what she had seen — the hundreds of wounded, many of their faces disfigured beyond recognition.“I am hoping that it was all just a bad dream,” Dr. El-Hallak said, still struggling to take stock of the carnage on Friday.Then, without warning, Israeli fighter jets ripped through the skies above Lebanon’s capital.“There are strikes in Dahiya?” she said in disbelief, using the Arabic name for Beirut’s southern suburbs.Her nightmare had only just begun.The attacks on Hezbollah’s communication devices this week — widely attributed to Israel — wounded thousands of people, leaving many of them permanently disabled and in need of long-term rehabilitative care. The Israeli airstrike just miles from downtown Beirut on Friday, which killed at least 37 people and injured dozens more, has only added to the toll. Others are still presumed trapped in the debris.Lebanon’s ailing health system — already embattled by a crippling economic collapse — has been sent into overdrive.Dr. Ghassan Abu Sitta at his home in London in December. He volunteered last year at a burn unit in Gaza and now believes war will come to Lebanon. Mary Turner for The New York TimesWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 125 Shares99 Views

      in Elections

      Elizabeth Warren: Don’t Be Fooled. Donald Trump Has a Plan.

      by

      During the presidential debate on Tuesday, Donald Trump was pressed on the details of his plan to repeal Obamacare and replace it with something “better.” The question should’ve been a softball. After all, Mr. Trump has been promising the American people a plan for nine years, so he’s had time to prepare. His answer? After ducking and weaving, he came up with: “I have concepts of a plan.” Uh, that’s not a plan.Plans translate values into action. They test the quality of the ideas and the seriousness of the people advancing them. Plans reveal for whom candidates will fight and how effective they are likely to be. And in a presidential race, if either party’s nominee is asked about his or her plans for something as fundamental as health care, voters should get a straight answer.The problem is not that Mr. Trump can’t think up a way to put his values into action. The problem is that when he and other Republican leaders produce plans with actual details, they horrify the American people.Mr. Trump’s health care values have been on full display for years. In 2017, Republicans controlled Congress, and their first major legislative undertaking was a bill to repeal the Affordable Care Act. Every time they drafted something, independent experts would point out that their plan would toss tens of millions of people off their health insurance, jack up premium costs and slash benefits for those with ongoing health problems.After months of wrangling, Mr. Trump and Republican lawmakers voted a bill through the House to repeal the A.C.A. That night, Mr. Trump hosted a party at the White House to celebrate their big step toward taking away health care from millions of people.A.C.A. repeal then moved to the Senate. Republicans had the majority, so if they all stuck with Mr. Trump, the A.C.A. would die. As senators gathered to vote, nearly all of the Democrats — including Kamala Harris, then a senator from California — remained standing, too anxious even to sit down. We murmured stories about who would be affected by this vote: the uncle who had cancer and would lose coverage, the kid diagnosed with a heart anomaly whose parents wouldn’t be able to find new insurance, the college students who would just go without coverage and hope they didn’t fall on ice or get in a car accident. We felt the weight of people’s lives on the line.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 125 Shares189 Views

      in Elections

      W.H.O. Authorizes Mpox Vaccine, Clearing Way for Use in Africa

      by

      The decision is a crucial step in getting shots to the Democratic Republic of Congo, the center of the outbreak.The World Health Organization has given its authorization to a first vaccine to protect against mpox, a decision announced in such haste on Friday that it caught even the head of the company that makes the vaccine by surprise.The vaccine, made by the Danish company Bavarian Nordic, has been approved by the regulatory authorities in Europe as well as the United States and other high-income countries since a global mpox outbreak in 2022. But low- and middle-income countries rely on the W.H.O., through a process called prequalification, to determine which drugs, vaccines and health technologies are safe and efficient uses of limited health funding, and the organization had declined to act until now.The W.H.O. had come under increasing criticism for declaring a global public health emergency for mpox last month without giving a vaccine that prequalification stamp of approval, or a more provisional form of approval called emergency use authorization. Bavarian Nordic first submitted its safety and effectiveness data on the vaccine, called Jynneos, to the W.H.O. in 2023. The W.H.O. had defended its slow pace of review, saying that it needed to subject the vaccine to careful study because it, and two others that have been used to protect against mpox, were originally designed as smallpox immunizations, and because delivering it in low-resource settings such as Central Africa would involve factors different from those relating to its use in high-income countries.But on Friday morning, the W.H.O. suddenly said it was authorizing the shot.“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” Dr. Tedros Adhanom Ghebreyesus, the W.H.O. director general, said in a statement.Paul Chaplin, Bavarian Nordic’s chief executive, said he was among the many who had been caught off guard.“We’ve got there eventually — I don’t know quite how,” he said. “But it’s good news. It’s going to make the regulatory pathway much easier.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 88 Shares159 Views

      in Elections

      Are Some Ultraprocessed Foods Worse Than Others?

      by

      A new study may offer the biggest clues yet.Name a common condition — heart disease, Type 2 diabetes, cancer, dementia, irritable bowel syndrome — and chances are good that following a diet high in ultraprocessed foods has been linked to it.But the ultraprocessed food category is large and wide-ranging. It makes up an estimated 73 percent of the U.S. food supply, and contains stereotypically “unhealthy” products like sodas, candies and hot dogs as well as seemingly “healthy” ones like whole grain breads, breakfast cereals, flavored yogurts and plant milks.It’s a “hodgepodge of foods,” some of which are likely more harmful than others, said Josiemer Mattei, an associate professor of nutrition at the Harvard T.H. Chan School of Public Health.On Monday, Dr. Mattei and her colleagues published one of the largest and longest studies on ultraprocessed foods and heart health to date. In it, they analyzed the risks of consuming these foods, and teased out the worst offenders.An Overall Risk of Ultraprocessed FoodsThe new study, published in a Lancet journal, included more than 200,000 adults in the United States. They filled out detailed diet questionnaires beginning in the 1980s and early 1990s, and completed them again every two to four years for about 30 years. Most of the participants in the study were white and worked as health professionals. The researchers looked at how the participants’ ultraprocessed food consumption related to their chances of developing cardiovascular disease.After adjusting for risk factors like smoking, family health history, sleep and exercise, the researchers found that those who consumed the most ultraprocessed foods were 11 percent more likely to develop cardiovascular disease and 16 percent more likely to develop coronary heart disease during the study period, compared with those who consumed the least ultraprocessed foods. The highest consumers also had a slightly, but not significantly, elevated risk of stroke.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More